Clinical trial NCT02095210: HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025
Official title: Phase 1 Study, Evaluating HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: HER2-positive Breast Cancer
Keywords: PET scan
HER2
breast cancer
Lead sponsor: Herlev Hospital
Sponsor class: OTHER
First posted: 2014-03-24
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is an open-labeled, exploratory, single center study. Patients with a big primary breast cancer (≥ 3 cm) or metastatic first line, routinely have their HER2-expression determined by biopsy. Patients having a HER2-positive tumor will be recruited to the study. A \[18F\]FDG PET/ceCT scan is performed for the measurement of uptake in the tumour and diagnosis of possible metastases. Each subject will receive a single injection of the investigational product \[68Ga\]ABY-025, followed by measurement of uptake in the tumour or metastases and in normal organs. The investigations will be repeated after HER2 directed therapy.

Detailed description: see above

Eligibility criteria: Inclusion Criteria:

1. Subject is \> 18 years of age
2. Histologically or cytologically confirmed diagnosis of breast adenocarcinoma ≥ 3 cm determined by ultrasound, or locally advanced breast cancer (LABC: T3-4NxMx or TxN2-3Mx)
3. HER2-positiv breast cancer first recurrence
4. HER2-positiv breast cancer primary metastatic
5. HER2 status has been determined on biopsy material from the primary tumour and found to be HER2-positive, defined as a DAKO HercepTest™ score of 3+ or else 2+ and FISH positive
6. \[18F\]FDG PET/ceCT performed within 7 days before administration of IMP
7. ECOG performance status of =\< 2
8. Hematological, liver and renal function test results within the following limits:

   * White blood cell count: \> 2.0 x 10\^9/L
   * Haemoglobin: \> 5.0 mmol/L
   * Platelets: \> 50.0 x 10\^9/L
   * ALT, ALP: =\< 3 times Upper Limit of Normal
   * Bilirubin =\< 2.0 times Upper Limit of Normal
   * Serum creatinine: Within Normal Limits
9. A negative pregnancy test (serum beta-HCG) at screening for all subjects of childbearing potential
10. Subject is capable to undergo the diagnostic investigations to be performed in the study
11. Informed consent

Exclusion Criteria:

* 1. Known hypersensitivity to Dotarem® 2. Active known autoimmune disease or history of autoimmune disease 3. Active serious infection according to investigator evaluation 4. Known HIV positive or chronically active hepatitis B or C 5. Administration of other investigational medicinal product within 30 days of screening 6. Pregnant or breast-feeding 7. Women capable of childbearing not using a sufficient non-hormonal method of birth control 8. Other primary malignancies (including primary brain tumors) within the last 5 years before inclusion, with exception of sufficiently treated in situ carcinoma of the cervix, squamous carcinoma of the skin or sufficiently controlled limited basal cell carcinoma of the skin 9. Signs of any other disease, metabolic or psychological dysfunction, findings at physical examination or laboratory findings, which give reasonable suspicion of a disease or condition that would contraindicate use of the IMP, could influence the patient's compliance with the study routines or involves an increased risk for treatment-related complications.

Primary outcomes:
measure: to evaluate the uptake distribution of the HER2-binding imaging agent [68Ga]ABY-025 by PET imaging in breast cancer patients with biopsy-identified HER2 expression
timeFrame: 28 days from last dose of study drug
Secondary outcomes:
measure: Assess concordance of [68Ga]ABY-025 uptake with [18F]FDG PET uptake before and after HER2 therapy
timeFrame: within 14 days before study drug
measure: 2. pharmacokinetics of [68Ga]ABY-025 and whole-body dosimetry of [68Ga]ABY-025
timeFrame: 6 weeks after last dose of study drug
Other outcomes:
Locations:
city: Herlev
country: Denmark
facility: Herlev University Hospital, Oncology Department
Study officials:
affiliation: Consultant
name: Malgorzata K Tuxen, MD, P.hd.
role: PRINCIPAL_INVESTIGATOR
References: